Procalcitonin: A possible marker of invasive fungal infection in high risk patients?

Journal of Preventive Medicine and Hygiene

Volumn 52, Issue 1, 2011, Pages 38-39

  Montagna, Maria Teresa ^a   Coretti, C ^a   Caggiano, G ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOMANNAN; PROCALCITONIN;

ARTICLE; ASPERGILLOSIS; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LEUKOCYTE; MYCOSIS; NEWBORN INTENSIVE CARE; NONHUMAN; PREMATURITY; VERY LOW BIRTH WEIGHT;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; CALCITONIN; CRITICAL ILLNESS; FUNGEMIA; HUMANS; PROTEIN PRECURSORS;

EID: 79958859498     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Prella M, Bille J, Pugnale M, et al. Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005;51:95-101.
2. Maertens J, Theunissen K, Lodewyck T, et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007;50(Suppl 1):2-17.
3. Laín A, Elguezabal N, Moragues MD, et al. Contribution of serum biomarkers to the diagnosis of invasive candidiasis. Expert Rev Mol Diagn 2008;8:315-25.
4. Ellis M, Al-Ramadi B, Bernsen R, et al. Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol 2009;58:606-15.
5. Pontón J. Usefulness of biological markers in the diagnosis of invasive candidiasis. Rev Iberoam Micol 2009;26:8-14.
6. Christ-Crain M, Muller B. Procalcitonin in bacterial infections - hype, hope, more or less? Swiss Med Wkly 2005;135:451-60
7. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-602.
8. Kato M, Kaneko S, Takagaki K, et al. Procalcitonin as a biomarker for toxic shock syndrome. Acta Derm Venereol 2010;90:441-3.
9. Meisner M, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006;10:R1.
10. Petrikkos GL, Christofilopoulou SA, Tentolouris NK, et al. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005;4:272-5.
11. Di Stefano G, Curreri R, Betta P, et al. Procalcitonin serum levels in perinatal bacterial and fungal infection of preterm infants. Acta Paediatric 2004;93:216-9.
12. Martini A, Gottin L, Menestrina N, et al. Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010;60:425-30.
13. Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999;134:49-55.
14. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001;32:1718-25.
15. Christofilopoulou S, Charvalos E, Petrikkos G. Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur J Intern Med 2002;13:493-5.
16. Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P, et al. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004;10:628-33.